CD49d Antibody [R1-2]

Product Specifications

Background

The R1-2 monoclonal antibody specifically reacts with mouse CD49d (integrin alpha 4), which forms the VLA-4 complex with CD29 (integrin beta 1) . VLA-4 is expressed on thymocytes, monocytes, and a subset of peripheral lymphocytes. It is the receptor for fibronectin and CD106 (VCAM-1) . CD49d also forms a receptor for mucosal vascular addressin (MAdCAM-1) with integrin beta 7.

NCBI Gene ID

16401

Swiss Prot

Q00651

Host

Rat

Reactivity

Mouse

Clonality

Monoclonal

Clone

R1-2

Conjugation

Unconjugated

Type

Primary Antibodies, Functional Antibodies

Field of Research

Immunology

Purification

The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/µg of the protein.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C . Do not freeze.

Fragment

Rat IgG2b, kappa

Specificity

The R1-2 monoclonal antibody specifically reacts with mouse CD49d (integrin alpha 4), which forms the VLA-4 complex with CD29 (integrin beta 1) .

Symbol

Itga4

NCBI Official Name

Integrin alpha 4

NCBI Organism

Mus musculus

Background Reference 01

Deckert, M., Kubar, J., Zoccola, D., Bernard‐Pomier, G., Angelisova, P., Horejsi, V., Bernard, A. (1992) . CD59 molecule: a second ligand for CD2 in T cell adhesion.European journal of immunology,22 (11), 2943-2947.

Background Reference 02

Korty, P. E., Brando, C. L. A. R. A., Shevach, E. M. (1991) . CD59 functions as a signal-transducing molecule for human T cell activation.The Journal of immunology,146 (12), 4092-4098.

Background Reference 03

Davies, A., Simmons, D. L., Hale, G., Harrison, R. A., Tighe, H., Lachmann, P. J., Waldmann, H. (1989) . CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.The Journal of experimental medicine,170 (3), 637-654.